Cardiff Oncology

Historical price data

Cardiff Oncology's mission is to develop novel cancer therapies by leveraging Polo-like kinase 1 (PLK1) inhibition. Its core achievement is advancing its lead asset, onvansertib, into multiple mid-stage clinical trials in combination with standard regimens for difficult-to-treat cancers like metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). The company's strategy is predicated on using onvansertib to target tumor vulnerabilities and overcome resistance to existing therapies, aiming to deliver superior clinical benefit. Cardiff's future is entirely tied to the clinical validation of this combination approach.

Centered on Polo-like kinase 1 (PLK1) inhibition, leveraging the target's role in cell cycle regulation to disrupt mitosis in cancer cells and, critically, to overcome resistance to standard-of-care therapies when used in combination.